vTv Therapeutics Inc.
No SEC Form 4 filings for $VTVT in the last 30 days.
See all $VTVT insider activity →vTv Therapeutics (VTVT) presented data on cadisegliatin, a potential type 1 diabetes treatment, showing HbA1c reductions in Phase Ib/IIa trials. The Phase III CATT1 trial aims to reduce hypoglycemia by 30% and has enrolled 166 participants. The company reported $86.6M in cash reserves, sufficient for operations beyond the trial's readout.
BTIG maintained a Buy rating on vTv Therapeutics (VTX) with a $57 price target, implying 101.9% upside from the Oct 13 close. The company is advancing its clinical pipeline, including cadisegliatin, which has FDA Breakthrough Therapy Designation, and plans Phase 3 and Phase 2a trials for T1D treatment.
vTv Therapeutics (VTVT) announced FDA Orphan Drug Designation for HPPD, its investigational treatment for sickle cell disease. HPPD showed promise in preclinical studies, increasing fetal hemoglobin and reducing oxidative stress. The company is also developing cadisegliatin for type 1 diabetes, which has Breakthrough Therapy designation.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VTVT (vTv Therapeutics Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VTVT coverage spans financial news, earnings and regulation.
Positive clinical‑trial milestone and regulatory designation may lift sentiment.
Analyst upgrade with a high price target may drive buying interest and upward price pressure.
Orphan designation may boost vTv's valuation by de‑risking the HPPD program and attracting partnership or financing.
Enrollment milestone removes a key execution risk and sets the path toward topline data in mid‑2027.
New coverage and higher target could spark buying pressure.
AlphAI scores every news story that mentions VTVT with an AI model for sentiment and relevance, and aggregates insider trades from vTv Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
vTv Therapeutics (VTVT) presented data on cadisegliatin, a potential type 1 diabetes treatment, showing HbA1c reductions in Phase Ib/IIa trials. The Phase III CATT1 trial aims to reduce hypoglycemia by 30% and has enrolled 166 participants. The company reported $86.6M in cash reserves, sufficient for operations beyond the trial's readout.
2 min readBTIG maintained a Buy rating on vTv Therapeutics (VTX) with a $57 price target, implying 101.9% upside from the Oct 13 close. The company is advancing its clinical pipeline, including cadisegliatin, which has FDA Breakthrough Therapy Designation, and plans Phase 3 and Phase 2a trials for T1D treatment.
1 min readvTv Therapeutics (VTVT) announced FDA Orphan Drug Designation for HPPD, its investigational treatment for sickle cell disease. HPPD showed promise in preclinical studies, increasing fetal hemoglobin and reducing oxidative stress. The company is also developing cadisegliatin for type 1 diabetes, which has Breakthrough Therapy designation.
2 min readvTv Therapeutics (VTVT) completed enrollment in its Phase 3 CATT1 study of cadisegliatin, a potential treatment for type 1 diabetes. The study randomized 166 patients and aims to assess the drug's efficacy in reducing hypoglycemia. Results are expected in mid-2027, according to the company.
2 min readRBC Capital's Brian Abrahams maintained a Hold rating on Kymera Therapeutics (KYMR) with a $112 price target, while LifeSci Capital's Patrick Dolezal initiated coverage on vTv Therapeutics (VTVT) with a Buy rating and $60 target. KYMR's consensus price target is $135.22, and VTVT's is $58.50.
2 min readvTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid
5 min readvTv Therapeutics (Nasdaq: VTVT) reported Q2 2026 results for the quarter ended June 30, 2026. The company said Phase 3 CATT1 cadisegliatin enrollment is expected to complete in Q3 2026 and it expects cash of $86.6M at June 30 to fund operations through the CATT1 topline readout. Q2 net loss was $13.1M, or $1.05/share.
5 min readvTv Therapeutics (Nasdaq: VTVT) said it granted inducement stock options to two non-executive employees under Nasdaq Rule 5635(c)(4): 12,500 options with a weighted average exercise price of $34.15. Options vest over four years (25% at one year, then quarterly for 36 months) and expire after 10 years, subject to plan terms.
2 min readvTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. vtvt-20260626 FALSE 0001641489 Nasdaq 0001641489 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event rep
2 min readvTv Therapeutics Inc. announced the grant of 39,500 stock options to two new non-executive employees as an inducement to employment, in compliance with Nasdaq Listing Rule 5635(c)(4). These options have a weighted average exercise price of $32.00 per share and will vest over four years, subject to continued employment. The company is a late-stage biopharmaceutical firm focused on developing cadisegliatin for type 1 diabetes.
2 min read
